CHICAGO, January 4, 2023 – GE Healthcare (Nasdaq: GEHC) announced today that the previously announced separation from GE Corporation (NYSE: GE) has been completed and that GE Healthcare will begin operating as an independent company in Nasdaq. DAK is listed on the Stock Exchange under the stock code “GEHC”, effective today.
It is reported that the split of GE Healthcare is completed by distributing approximately 80.1% of GE Healthcare’s shares held by GE in accordance with the shareholding ratio of GE’s existing shareholders. GE will retain approximately 19.9 percent of GE Healthcare’s outstanding common stock after the split.
Up to now, GE Healthcare has about 51,000 employees in more than 160 countries around the world, serving more than 1 billion patients every year; the company invests more than 1 billion U.S. dollars in research and development every year, with an annual revenue of about 18 billion U.S. dollars and more than 4 million units. Global installed capacity, covering the company’s four major business segments – medical imaging, ultrasound, life care and drug diagnosis.
GE Healthcare expects the company’s addressable market to grow from $84 billion in 2021 to $102 billion in 2025. This growth will provide an opportunity for the company to advance the execution of its precision medicine strategy, which integrates patient data from medical imaging, laboratory, pathology, genomics and other sources. With Edison’s digital medical intelligence platform and application software, precision medicine will stratify data through artificial intelligence. This precision medicine strategy provides a basis for clinicians to diagnose diseases and determine more suitable treatment options, so that patients can enjoy better treatment outcomes.
China has always been one of the largest markets for GE’s medical sector, especially in terms of medical imaging equipment. GE Medical, Philips, and Siemens are also known as “GPS”, accounting for half of the domestic market. At present, China has become the second largest market of GE Healthcare in the world, which brings huge opportunities for the development of GE Healthcare.
As Zhang Yihao, president and CEO of GE Healthcare China, said in an interview with 36 Krypton, GE Healthcare will also enter a new era and become an independent listed company. “This allows us to focus more on the medical industry and introduce more investment into this industry to serve Chinese medical users.” At the same time, the independent medical business will also promote innovation in the field of precision medicine, focusing on improving patient prognosis and disease Diagnosis and treatment level, responding to severe challenges faced by patients and clinics.
In recent years, under the background of domestic manufacturing, GE Healthcare has gradually promoted the localization of all high-end, high-end and low-end products, covering product, supply chain, innovation and other aspects, and strives to realize the full domestic production of GE Healthcare’s full range of products in the future. Chinese customers provide products, services and solutions that meet the needs of the Chinese market and patients.
Taking medical imaging as an example, GE Healthcare has launched new products with higher performance frequently in China in recent years. For example, just half a month ago, GE Healthcare China released a CT product with Chinese characteristics that meets the needs of large-volume imaging examinations in outpatient and emergency departments——Revolution Maxima Select, which allows inspection equipment to improve scanning speed, image quality, The diagnostic efficiency has been greatly improved, and it can be widely used in diagnostic scenarios such as the elderly, critically ill, hearing impaired, and respiratory diseases.
media reports
Sina Titanium Media 36Kr 36Kr
related events
- GE Healthcare completed the split and listed on Nasdaq, continuing to promote precision medical innovation2023-01-05
- Parkview Medical received A+ round of financing2022-08-24
- Dehong Capital completed the exclusive strategic investment in Meihua Medical2022-06-20
- The hottest new stock at the end of the year, Yonghe Medical, officially landed on the Hong Kong Stock Exchange and rose by more than 5% at the opening, becoming the “first hair transplant stock” 2021-12-13
- Delta Medical raised more than US$100 million and received strategic investment from Swire Pacific Limited2021-09-17
This article is transferred from: https://readhub.cn/topic/8mj1MHIDUpI
This site is only for collection, and the copyright belongs to the original author.